Search PubMed⌕ Search

Biomedical subjects

S C Scheiber

Publications and source records attributed to S C Scheiber.

12 recordsLinked to original sources
PubMed1991

Certification and recertification.

The American Board of Psychiatry and Neurology issues certificates for psychiatrists in general psychiatry, child and adolescent psychiatry, and added qualification in geriatric psychiatry. It will issue a certificate in added qualification in clinical neurophysiology in 1992. An application for a certificate in added qualification in addiction psychiatry is currently under review by the American Board of Medical Specialties. The American Psychiatric Association has requested that the ABPN consider forensic psychiatry for an added qualification. All new subspecialty certificates will have a ten year time limit. Beginning on October 1, 1994, all certificates will be time-limited. Time-limited certificates will lead to the requirement for recertification. Current requirements for certification are reviewed and strategies for planing for recertification are discussed.

Adolescent Psychiatry↗
PubMed1991

Reliability of the Part II Board Certification Examination in Psychiatry: interexaminer consistency.

OBJECTIVE: The aim of the study was to examine the reliability (interexaminer consistency) of the American Board of Psychiatry and Neurology (ABPN) Part II (oral) examination in psychiatry. METHOD: Grades were assigned independently by two examiners who observed the same examination in a 1-year cycle (1,422 candidates, two examinations each). The consistency between these pairs of grades (pass, condition, fail) was analyzed using a weighted kappa statistic. RESULTS: There was perfect agreement between examiners in 67% of examinations, minor disagreement in 26%, and major disagreement in 7% (weighted kappa = 0.54-0.56). CONCLUSIONS: The Part II ABPN examination demonstrates fair to good reliability as measured by interexaminer consistency. Development of more explicit grading criteria should further improve examiner agreement in future examinations.

Educational Measurement↗
PubMed1979

Why should dialysis benefit schizophrenia?

If dialysis is successful for the treatment of schizophrenia, the artificial kidney must be removing something which the human kidney cannot, unless other nonspecific factors are involved. Either there is an abnormal compound present which is retained by normal renal tubular transport processes, or the kidney of a schizophrenic must be abnormal in that it fails to excrete a normally present compound. Since the latter explanation is less probable, biochemical research should focus on classes of compounds which are known to be handled differently by the artificial kidney than by the human kidney. A dialyzable "schizophrenic toxin" might be a nonprotein, nonprotein-bound of molecular weight below 500 daltons such as an organic acid or base. Proteins, peptides, amino acids, and trace elements are less likely possibilities.

Amino Acids↗
PubMed1976

Clinical and psychological test findings in cerebral dyspraxia associated with hemodialysis.

Cerebral dyspraxia associated with hemodialysis is a progressive, fatal syndrome. Patients suffer from a combination of psychiatric and neurological signs and symptoms. Psychiatric manifestations include anxiety, depression, paranoid ideation, and a progressive dementia with impaired concentration, decreased memory, personality changes, and hallucinations. Neurological findings include deliberate speech, stuttering, dysarthria, dyspraxia of speech and movement, tremulousness, myoclonic activity, asterixis, and seizures. These symptoms are aggravated during and immediately following dialysis. Patients usually die within 6 months of its onset. The etiology is unknown. Treatment efforts have failed to reverse its course. Recognition of this syndrome is highlighted so that informed, critical decisions can be made as to whether to continue dialysis therapy.

Adult↗